CBI

Leading life science success

CBI is Israel’s largest life sciences holding company

about cbi

Clal Biotechnology Industries (TASE: CBI) is Israel’s leading life sciences investment company. CBI supports life sciences by identifying and powering science backed ventures and proactively guiding them to transform the healthcare industry.

portfolio

The CBI portfolio is comprised of biotechnology and medical device companies developing breakthrough solutions for serious unmet medical needs, while offering substantial value and investment potential.

+

MediWound

MediWound (Nasdaq: MDWD) is a specialty biotechnology company focused on the fields of severe burn and chronic wound management.
+

Gamida Cell

Gamida Cell is a cell and immune therapy visionary. Lead product, NiCord® is currently in phase III clinical trial in hematological malignancies.
+

Anchiano (formerly Biocancell)

Anchiano Therapeutics (TASE: ANCN) is a clinical stage biopharmaceutical company dedicated to developing new therapies for non-muscle-invasive bladder cancer.
+

Elicio

Elicio develops platform technologies to deliver agents directly to the antigen-presenting cells of the lymph nodes with many potential applications in cancer
+

Neon Therapeutics

Neon Therapeutics (Nasdaq: NTGN) is a clinical stage, immuno-oncology company focused on developing novel therapeutics leveraging neoantigen biology to treat cancer.
+

Cadent Therapeutics

Cadent Therapeutics is developing novel drugs for neurological and psychiatric disorders.
+

Exithera

eXIthera Pharmaceuticals is a clinical stage biotech company focused on discovering and developing Factor XIa inhibitors for the prevention of stroke and thrombosis.
+

Biokine

Biokine Therapeutics is company focused on developing novel therapeutics to treat cancer. It's lead product, BL-8040, is licensed to BiolineRx and is in phase III clinical development.
+

CureTech

CureTech is a biotechnology company developing novel immune modulating products. Its lead product, pidilizumab (CT-011), was evaluated in multiple cancer indications.

See complete portfolio

Press Releases

2019

30

May

Cadent Therapeutics Announces FDA Orphan Drug Designation for CAD-1883 for Spinocerebellar Ataxia
29

May

BARDA Increases Support for NexoBrid with an Additional $21 Million to Fund Continuous Access Treatment Protocol for Thermal Burns
26

May

Pi-Cardia’s First-in-Human Study Shows Significant Improvement in Aortic Valve Function With its Novel Non-Implant Leaflex™ Catheter
26

May

Cadent Therapeutics Receives Milestone Payment from Novartis for Initiation of Phase II Trial of MIJ821 in Treatment-Resistant Depression
07

May

MediWound Enters into Exclusive License Agreement with Vericel for Commercial Rights to NexoBrid® in North America
14

Apr

כלל תעשיות ביוטכנולוגיה בע”מ : כינוס אסיפה כללית שנתית; יום ג’, 21 במאי 2019

Read all Press Releases